[Renal protective effects of specific XXXX inhibitor in @entity35 with @entity8 ].

@entity644 @entity13586 @entity8 @entity20033 @entity1809 @entity1808 @entity9378 @entity7489 @entity631 @entity9886 @entity3448 @entity9774 @entity38155 @entity810 @entity35 @entity3352 @entity11154 @entity4645
OBJECTIVE: To investigate the renoprotective effect of specific @entity4645 ( @entity4645 ) inhibitor @entity13586 and its possible mechanism of retarding progressive @entity8 in @entity35 with @entity8 . METHODS: @entity35 were randomly divided into six groups: sham, @entity8 (SNX). SNX treated with @entity13586 (10 mg.kg(-1).d(-1)). SNX treated with @entity3352 (2 mg.kg(-1).d(-1)). SNX treated with @entity9886 (100 mg.kg(-1).d(-1)). SNX treated with @entity13586 and @entity9886 . Blood pressure, urinary protein and @entity7489 ( @entity3448 ) were measured at the 6th week after operation and morphological changes were examined with light microscopy. The mRNA expression of transforming growth factor-beta type I and type II receptors ( @entity20033 , @entity38155 ) was detected by way of reverse transcription polymerase chain reaction. The expression of @entity9378 ( @entity9378 ), fibronectin (FN) and @entity11154 was examined utilizing Western blotting or immunohistochemistry. RESULTS: The levels of urinary protein and TXB(2) as well as cortical @entity4645 expression in SNX group were significantly increased while @entity9774 expression remained undisturbed in comparison with those in sham group. The levels of systolic blood pressure and @entity1808 in renal cortex significantly increased. The expression of @entity20033 and @entity38155 mRNA, @entity9378 and @entity1809 protein was up-regulated. The @entity631 index (GSI) and @entity810 index were increased in SNX group. @entity13586 significantly inhibited the increase in @entity644 and reduced GSI and @entity810 index. The expression of @entity20033 , @entity38155 and @entity9378 was down-regulated by 36.44%, 45.02% and 31.16% respectively, similar to the effect of @entity9886 treatment. @entity3352 significantly decreased @entity644 and slightly reduced GSI. However the @entity810 index was exacerbated. Systolic blood pressure was not significantly blunted in the groups of @entity13586 and @entity3352 . There was no significant additive effect of combined therapy with @entity9886 and @entity13586 , though @entity644 was reduced to a lower level. CONCLUSION: @entity13586 attenuates @entity644 and retards the progressive @entity8 in @entity35 with @entity8 partly by inhibition of @entity4645 activity and modulation of activation of renal renin-angiotensin system as well as the down-regulation of transforming growth factor-beta type I and type II receptors and @entity9378 .
